Open AccessThe therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study
Author(s) -
Dirk Blom,
Naresh Ranjith,
P Joshi,
Poobalan Naidoo,
André van Tonder,
Moji G. Musa,
Shaifali Joshi,
Rory Leisegang,
Julien Trokis,
Hemant Makan,
Frederick J. Raal
Publication year - 2020
Publication title -
cardiovascular journal of south africa/cardiovascular journal of southern africa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.378
H-Index - 35
eISSN - 1680-0745
pISSN - 1015-9657
DOI - 10.5830/cvja-2020-010
Subject(s) - ezetimibe , medicine , statin , cross sectional study , observational study , risk factor , lipid profile , cholesterol , pathology
Dyslipidaemia is a major modifiable risk factor for atherosclerotic cardiovascular disease. At the time the study was conducted, guidelines recommended a low-density lipoprotein cholesterol (LDL-C) target of less than 1.8 mmol/l and a reduction of at least 50% if the baseline LDL-C was between 1.8 and 3.5 mmol/l in patients with either very high cardiovascular risk or established atherosclerosis. In South Africa, there is a paucity of data on attainment of LDL-C goal in patients with very high cardiovascular risk who are on maximum tolerated statin with or without ezetimibe.